hMSTN

Fig.1 Detection of MSTN expression in mammary gland by RT-PCR. 

Wild type: only one band at 135 bp with primers F1/R1(mMstn);

Homozygous: only one band at 291 bp with primers F2/R2(hMSTN).

Abbr. M, DNA marker; HO, homozygous; WT, wild type.

Fig.2 Detection of hMSTN(A) and mMSTN(B) expression in serum by ELISA (female, 7-8wks, n=3). 

Abbr.  HO, homozygous; WT, wild type.

Note. The Human MSTN ELISA Kit cross-reacted with mouse MSTN and humanized MSTN.

Fig.3 Detection of (A) human and (B) mouse MSTN levels in serum from homozygous hMSTN knock-in mice and WT mice by ELISA. Human and mouse MSTN was detectable in serum from homozygous hMSTN knock-in mice and WT mice using the ELISA kits cross-reactive between human and mouse MSTN. Serum were collected from wild-type C57BL/6 mice (n=5) and homozygous hMSTN knock-in mice (n=6), and analyzed by ELISA with an anti-human MSTN ELISA kit and an anti-mouse MSTN ELISA kit. 

Abbr.  HO, homozygous; WT, wild type.

Fig.4 Detection of (A) human and (B) mouse MSTN levels in serum from homozygous hMSTN knock-in mice and WT mice by ELISA. Human and mouse MSTN was detectable in serum from homozygous hMSTN knock-in mice and WT mice using the ELISA kits cross-reactive between human and mouse MSTN. Serum were collected from wild-type C57BL/6 mice (n=5) and homozygous hMSTN knock-in mice (n=6), and analyzed by ELISA with an anti-human MSTN ELISA kit and an anti-mouse MSTN ELISA kit. 

Abbr.  HO, homozygous; WT, wild type.

Fig.5 In vivo efficacy of a human MSTN-targeting siRNA drug in hMSTN mice (Data from a collaborator). 

Homozygous hMSTN mice were randomly divided into two groups (female, 7 weeks old, n=5/group). Mice were administered a siRNA drug, containing the sequence from AD06569 drug. Serum MSTN levels were detected before and after dosing in hMSTN mice. Compared to the vehicle group, the siRNA treatment group demonstrated a significant decrease in serum MSTN levels. (Mean±SEM. Unpaired t-test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001).

Fig.6 The efficacy evaluation of test  articles in hMSTN mouse model (Male, 6-week-old, n=7).

Fig.7 The efficacy evaluation of test  articles in hMSTN mouse model. Both MSTN receptor antibodies and MSTN antibodies can increase muscle mass and reduce fat mass in hMSTN mice (Male, 6-week-old, n=7).

Fig.8 Pharmacodynamic validation in the HFD-Induced hMSTN Obese Mouse Model. Body weight changes and food intake measurement of Semaglutide combined with MSTN (GDF8) antibody and MSTN receptor antibody in hMSTN mice fed a high‑fat diet (Male, 6-8-week-old).

Fig.9 Body composition of the HFD-Induced hMSTN Obese Mouse  Model. Detection of fat and muscle changes in hMSTN mice fed a high‑fat diet following combined administration of Semaglutide, MSTN (GDF8) antibody, and MSTN receptor antibody (Male, 6-8-week-old).

Fig.10 Fasting blood glucose and tissue weight of the HFD-Induced hMSTN Obese Mouse  Model. Detection of various tissue indices in hMSTN mice fed a high‑fat diet following combined administration of Semaglutide, MSTN (GDF8) antibody, and MSTN receptor antibody (Male, 6-8-week-old).